⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.
SYNGENE - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 3.4
| Stock Code | SYNGENE | Market Cap | 16,881 Cr. | Current Price | 419 ₹ | High / Low | 761 ₹ |
| Stock P/E | 44.0 | Book Value | 115 ₹ | Dividend Yield | 0.30 % | ROCE | 12.8 % |
| ROE | 9.78 % | Face Value | 10.0 ₹ | DMA 50 | 475 ₹ | DMA 200 | 593 ₹ |
| Chg in FII Hold | -1.35 % | Chg in DII Hold | 1.21 % | PAT Qtr | 68.7 Cr. | PAT Prev Qtr | 66.2 Cr. |
| RSI | 41.4 | MACD | -18.8 | Volume | 9,08,300 | Avg Vol 1Wk | 28,94,356 |
| Low price | 381 ₹ | High price | 761 ₹ | PEG Ratio | 34.1 | Debt to equity | 0.07 |
| 52w Index | 9.87 % | Qtr Profit Var | -44.2 % | EPS | 8.22 ₹ | Industry PE | 52.3 |
📊 Technical Analysis
- Chart Patterns: Stock has corrected sharply from highs of ₹761, currently stabilizing near ₹419 with support at ₹381–₹400 and resistance around ₹475 (50 DMA).
- Moving Averages: Price (₹419) below both 50 DMA (₹475) and 200 DMA (₹593), confirming bearish trend.
- RSI: 41.4 — approaching oversold zone, suggesting limited downside.
- MACD: -18.8 — bearish crossover, momentum negative.
- Bollinger Bands: Price near lower band, oversold condition may trigger short-term bounce.
- Volume Trends: Current volume (9.08 Lakh) well below 1-week average (28.9 Lakh), showing weak participation.
📈 Momentum & Signals
- Short-term Momentum: Weak, with bearish bias but oversold signals hint at possible rebound.
- Entry Zone: ₹381–₹419 (support region).
- Exit Zone: ₹470–₹490 (resistance region).
- Trend Status: Reversing from uptrend to bearish consolidation.
✅ Positive
- DII holdings increased (+1.21%).
- Low debt-to-equity ratio (0.07), financially stable.
- EPS at ₹8.22, showing profitability despite correction.
⚠️ Limitation
- Stock P/E (44.0) above industry average (52.3), but valuations stretched given weak earnings growth.
- PEG ratio at 34.1, showing expensive valuation relative to growth.
- Price below both 50 DMA and 200 DMA, confirming bearish trend.
- ROCE (12.8%) and ROE (9.78%) relatively weak.
📉 Company Negative News
- Quarterly profit variation (-44.2%) highlights declining profitability.
- Sequential PAT stagnation (₹68.7 Cr vs ₹66.2 Cr).
- Weak 52-week performance (9.87%), underperforming peers.
📈 Company Positive News
- DII participation increased, showing domestic institutional confidence.
- Low leverage ensures financial stability.
🧪 Industry
- Biotech & pharma services sector PE at 52.3, showing higher valuations compared to SynGene’s P/E of 44.0.
- Industry supported by global demand for contract research and drug development services.
🔎 Conclusion
- SYNGENE is in a bearish phase, trading well below key moving averages.
- Oversold RSI and Bollinger Band signals suggest potential rebound near ₹381–₹419.
- Short-term traders can accumulate near support and exit around ₹470–₹490.
- Long-term investors should be cautious due to weak profitability metrics and stretched valuations despite sectoral demand.